Baudouin “Bo” Standaert was born in Bruges, Belgium. He studied medicine (MD) at the KU Leuven and Tropical Medicine in Antwerp (1982). During the first 7 years of his career Bo had a mixed work assignment in academia (University of Antwerp and UCL in Brussels) and abroad (Suriname, Burundi, Salomon islands, WHO (Geneva)). In 1988 he became director of the Provincial Institute of Hygiene in Antwerp. The Institute had around 160 employees split into lab and field work in collecting basic health and environmental information. During that period Bo was the representative of Belgium in the scientific board of IARC in Lyon, France for 4 years. His interest in economic evaluations of health care emerged with the collaboration with the University of Antwerp in 1990. At that time different pharmaceutical companies were interested in getting HE-expertise in house. Bo took the decision in 1995 to join AMGEN to become their first health economist in Europe. A small team of 8 people was set up in Brussels coordinating all their HE-activities. In 2005, it was time to move to another international group in Belgium and to start working on vaccines. Bo became the head of the global HE-team of vaccines in GSK, Wavre, Belgium. He started with 3 collaborators, first working on Rotarix and Cervarix and later on Synflorix. The group counts now 12 persons. The HE-team has a wide experience in developing different types of economic assessments from simple back-of-the envelope models to more advanced dynamic and macro-economic models for pandemic infectious diseases such as malaria, TB, HIV, Flu. The HE-team explores new economic value evidence (Quality of Care, absenteeism, herd effect) away from the conventional cost-effectiveness analysis including optimisation modelling, return on investment, and fiscal modelling. Bo has numerous publications in the many different fields he worked on. He obtained his PhD on rotavirus vaccination, exploring new ways of economic assessment, at the University of Groningen, the Netherlands, in 2015. He was the industrial representative of the WHO-IVIR-working group for 9 years. He co-chaired the taskforce on economic evaluation of vaccines for ISPOR (2016-2018) and was recently appointed industrial lead for the European IMI-Vital (2018-2022) project on vaccination in elderly.